Imiquimod chemoprophylaxis for field cancerization in xeroderma pigmentosum patients-A prospective study

Affiliations

¹ Department of Dermatology, Hospital das Clínicas of São Paulo University, São Paulo, Brazil.
² Hospital das Clínicas of São Paulo University, São Paulo, Brazil.
³ Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
⁴ Laboratory of Dermatologia Tropical, Hospital das Clínicas of São Paulo University, São Paulo, Brazil.

Lílian Kelly Faria Licarião Rocha et al. Australas J Dermatol. 2023 Aug.

. 2023 Aug;64(3):435-438.

doi: 10.1111/ajd.14029. Epub 2023 Apr 13.

¹ Department of Dermatology, Hospital das Clínicas of São Paulo University, São Paulo, Brazil.
² Hospital das Clínicas of São Paulo University, São Paulo, Brazil.
³ Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
⁴ Laboratory of Dermatologia Tropical, Hospital das Clínicas of São Paulo University, São Paulo, Brazil.

No abstract available

References

1. DiGiovanna JJ, Kraemer KH. Shining a light on Xeroderma Pigmentosum. J Investig Dermatol. 2012;132:785-96.
1. Hanna E, Abadi R, Abbas O. Imiquimod in dermatology: an overview. Int J Dermatol. 2016;55(8):831-44.
1. Lambert WC, Lambert MW. Development of effective skin cancer treatment and prevention in Xeroderma Pigmentosum. Photochem Photobiol. 2015;91:475-83.
1. Latour I, Hernández-Martín A, Ged C, Knöpfel N, Taïeb A, Torrelo A. Reversed actinic damage in two children with xeroderma pigmentosum treated with topical imiquimod. J Eur Acad Dermatol Venereol. 2018;32(7):282-e284.